Vico receives $60M funding to support novel therapy for neurodegenerative conditions
Click Here to Manage Email Alerts
A clinical-stage genetic medicine firm has announced $60 million in Series B financing to support a phase 1/2 clinical trial and advance its lead candidate to treat spinocerebellar ataxia types 1 and 3 as well as Huntington’s disease.
According to a release from Vico Therapeutics, the forthcoming study will examine safety and tolerability of multiple ascending doses of intrathecal VO659 in participants with mild to moderate SCA3, SCA1 and early manifest HD, with the first patient expected to be dosed in April.
The latest round of funding will also help support discovery and research efforts to further expand Vico’s studies in other genetic neurological diseases, according to the release.
According to the release, the cash infusion was led by new investor Ackermans & van Haaren with existing co-leads Droia Ventures, EQT Life Sciences and Kurma Partners along with prior investors Polaris Partners, Pureos Bioventures and Eurazeo.
“We are pleased that a team of highly sophisticated investors has joined in this financing round, further validating our progress and the significant potential of VO659 to transform the lives of patients living with these devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available,” Vico CEO Micah Mackison said in the release.